Fiduciary Alliance LLC grew its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 7.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,879 shares of the company’s stock after purchasing an additional 836 shares during the quarter. Fiduciary Alliance LLC’s holdings in Guardant Health were worth $363,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in Guardant Health by 188.6% during the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after purchasing an additional 6,618,785 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Guardant Health by 1,282.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after buying an additional 1,137,482 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Guardant Health by 233.5% during the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock worth $34,701,000 after buying an additional 1,059,104 shares during the period. Erste Asset Management GmbH bought a new stake in shares of Guardant Health in the 3rd quarter valued at $21,389,000. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Guardant Health during the 3rd quarter valued at $15,624,000. Institutional investors own 92.60% of the company’s stock.
Insider Buying and Selling at Guardant Health
In other news, Director Musa Tariq sold 2,320 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,432 shares of company stock worth $175,423 in the last quarter. 5.50% of the stock is currently owned by company insiders.
Guardant Health Price Performance
Guardant Health (NASDAQ:GH – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The firm had revenue of $191.48 million during the quarter, compared to analysts’ expectations of $170.49 million. During the same quarter last year, the business posted ($0.73) EPS. The company’s quarterly revenue was up 33.9% on a year-over-year basis. As a group, analysts anticipate that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on GH shares. Sanford C. Bernstein reduced their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. The Goldman Sachs Group raised their target price on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Leerink Partners cut their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Fifteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $40.60.
Check Out Our Latest Stock Analysis on Guardant Health
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
- Five stocks we like better than Guardant Health
- How to invest in marijuana stocks in 7 stepsĀ
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Overbought Stocks Explained: Should You Trade Them?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Basic Materials Stocks Investing
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.